Aarti Drugs Q3 PAT more than doubles yoy at Rs68cr

Aarti Drugs reported 11.98% growth yoy in Dec-20 quarter consolidated revenues at Rs530.25cr

Jan 25, 2021 03:01 IST India Infoline News Service

Aarti Drugs
Aarti Drugs reported 11.98% growth yoy in Dec-20 quarter consolidated revenues at Rs530.25cr. Like most of the pharma and pharma intermediate companies, Aarti Drugs also saw a very sharp spike in sales in the Sep-20 quarter when COVID sales had scaled new highs. However, the latest quarter sales are lower than sales on QOQ basis.

For the Dec-20 quarter, the consolidated operating profits were up 68.89% at Rs93.11cr. The company saw sales revenues growing much faster than the cost leading to better fixed cost absorption. The OPM expanded sharply from 11.64% in the Dec-19 quarter to 17.56% in Dec-20 quarter.

The consolidated Profit after tax (PAT) for the Dec-20 quarter was up 144.54% at Rs68.03cr on better operational performance in the quarter. As a result, the PAT margins more than doubled from 5.88% in Dec-19 to 12.83% in Dec-20.

Financial highlights for Dec-20 compared yoy and sequentially


Aarti Drugs
Rs in Crore Dec-20 Dec-19 YOY Sep-20 QOQ
Total Income (Rs cr) ₹ 530.25 ₹ 473.51 11.98% ₹ 578.11 -8.28%
Operating Profit (Rs cr) ₹ 93.11 ₹ 55.13 68.89% ₹ 103.88 -10.37%
Net Profit (Rs cr) ₹ 68.03 ₹ 27.82 144.54% ₹ 75.27 -9.62%
Diluted EPS (Rs) ₹ 7.30 ₹ 2.98 ₹ 8.08
OPM 17.56% 11.64% 17.97%
Net Margins 12.83% 5.88% 13.02%
 

Related Story

Open Free Demat Account (Rs699)